Evaluating the role of radiology manipulators in cancer imaging interpretation
COOPERATION BETWEEN THE MEDICAL ELECTRORADIOLOGY MANIPULATOR (MEM) AND THE RADIOLOGIST IN TUMOR IMAGING ASSESSMENTS: CIMER-IPC 2023-030
This study is testing if a new tool can help doctors read cancer imaging better and faster by checking their work before they make a final report.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 87 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Paoli-Calmettes Academic / other |
| Locations | 1 site (Marseille, Institut Paoli Calmettes) |
| Trial ID | NCT06894082 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effectiveness of medical electroradiology manipulators (MEMs) in validating radiological work related to solid cancers using the RECIST 1.1 criteria. Patients involved in the CIMER study will undergo baseline examinations without informing the radiologists to avoid bias. The MEMs will conduct preliminary analyses of imaging results and present them to the radiologists for validation. This approach seeks to enhance the quality of radiological reports and reduce interpretation time amidst increasing workloads in oncology imaging.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over with measurable solid cancers included in a clinical research protocol requiring RECIST 1.1 interpretation.
Not a fit: Patients with lymphoma, leukemia, or those unable to undergo medical follow-up for various reasons may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy and efficiency of cancer imaging interpretations, leading to better patient management.
How similar studies have performed: Preliminary findings from similar cooperative reading protocols have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female aged 18 and over * Patient included in a clinical research protocol in oncology for solid cancer including RECIST 1.1 interpretation * Disease measurable according to RECIST 1.1 * Patient not objecting to study participation * Member of a social security scheme, or beneficiary of such a scheme. Non inclusion Criteria: * Patients with lymphoma or leukemia * Patient contraindicated to iodinated contrast media injection * Person in an emergency situation, adult subject to a legal protection measure (major under guardianship, curatorship or safeguard of justice), or unable to express, his/her non-opposition to participate in the study * Unable to undergo medical follow-up for geographical, social or psychological reasons. or psychological reasons. Exclusion Criteria: * Patient with renal insufficiency or allergy during the trial no longer allowing injection of iodinated contrast medium * Patient refusing iodinated PDC injection during the study * Patient withdrawn from the study including scanner interpretation in Recist 1.1
Where this trial is running
Marseille, Institut Paoli Calmettes
- Institut PAoli Camettes — Marseille, Institut Paoli Calmettes, France (Recruiting)
Study contacts
- Study coordinator: Jihane PAKRADOUNI, Pr
- Email: pakradounij@ipc.unicancer.fr
- Phone: 0491223824
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.